Background: Hyperkalemia increases risk of cardiac arrhythmias and death and limits the
use of renin-angiotensin-aldosterone system inhibitors and mineralocorticoid receptor …

Membrane voltage controls the function of excitable cells and is mainly a consequence of
the ratio between the extra-and intracellular potassium concentration. Potassium …

Renin-angiotensin-aldosterone system (RAAS) inhibitors are evidence-based treatments for
a number of conditions including hypertension, diabetes mellitus, chronic kidney disease …

Aims Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits
the optimal use of agents that block the renin–angiotensin–aldosterone system, particularly …

Background This observational cohort study compared the likelihood of maintained
(stabilized/up-titrated) renin–angiotensin–aldosterone system inhibitor (RAASi) therapy at 6 …

Concerns about hyperkalemia may result in the underuse of established and novel
therapies that improve kidney and/or cardiovascular (CV) outcomes in patients with type 2 …

Abstract Background The KBindER (K+ Binders in Emergency Room and hospitalized
patients) clinical trial is the first head-to-head evaluation of oral potassium binders (cation …

Background: Diagnosis and treatment of primary aldosteronism (PA) in chronic kidney
disease (CKD) may be deferred due to limited evidence supporting safety and efficacy of …

The aim of this study was to develop a model for early prediction of adverse events and
treatment effectiveness in patients with hyperkalemia. We collected clinical data from …

Background Hyperkalemia (HK) is a barrier to optimization of renin-angiotensin-aldosterone
system inhibitor (RAASi) therapy in heart failure (HF) and chronic kidney disease (CKD). We …